Subject: Hemlibra 2417-A, 3536-A SGM P2023

Drug

HEMLIBRA  (emicizumab-kxwh)

Policy:

      I.  INDICATIONS

          The indications below including FDA-approved indications and
          compendial uses are considered a covered benefit provided
          that all the approval criteria are met and the member has no
          exclusions to the prescribed therapy.

          FDA-Approved Indications
          Hemlibra is indicated for routine prophylaxis to prevent or
          reduce the frequency of bleeding episodes in adult and pediatric
          patients ages newborn and older with hemophilia A (congenital
          factor VIII deficiency) with or without factor VIII inhibitors.

          All other indications are considered experimental/investigational
          and not medically necessary.

 
    II.  DOCUMENTATION

          Submission of the following information is necessary to initiate
          the prior authorization review:
          For continuation requests: Chart notes documenting benefit from
          therapy (e.g., reduced frequency or severity of bleeds).

 
  III.  PRESCRIBER SPECIALTIES

          Must be prescribed by or in consultation with a hematologist.

 
   IV.  CRITERIA FOR INITIAL APPROVAL

          Hemophilia A (congenital factor VIII deficiency)
          Authorization of 12 months may be granted for treatment of
          hemophilia A (congenital factor VIII deficiency) when all of the
          following criteria is met:
          A.  Member must be using the requested medication for routine
               prophylaxis to prevent or reduce the frequency of bleeding
               episodes.
          B.  Member meets one of the following criteria:
               1.  Member has mild disease (See Appendix A) and has had
                    an insufficient response to desmopressin or a
                    documented clinical reason for not using desmopressin
                    (See Appendix B).
               2.  Member has moderate or severe disease (See Appendix
                    A).
          C.  Prophylactic use of factor VIII products (e.g., Advate,
               Adynovate, Eloctate) will be discontinued after the first week
               of starting therapy with the requested medication.

 
     V.  CONTINUATION OF THERAPY

          Authorization of 12 months may be granted for continued
          treatment in members requesting reauthorization for an
          indication listed in Section IV when the member is experiencing
          benefit from therapy (e.g., reduced frequency or severity of
          bleeds) and member is not using the requested medication in
          combination with factor VIII products (e.g., Advate, Adynovate,
          Eloctate, etc.) for prophylactic use.

 
   VI.  DOSAGE AND ADMINISTRATION

          For initial and continuation requests, dosing does not exceed the
          following:
          A.  Induction: 3mg/kg subcutaneously once weekly for the first 4
               weeks.
          B.  Maintenance: 1.5mg/kg once weekly, or 3mg/kg once every
               2 weeks, or 6mg/kg once every 4 weeks.

 
  VII.  APPENDICES

          Appendix A: Classification of Hemophilia by Clotting
          Factor Level (% Activity) and Bleeding Episodes

Severity	Clotting Factor Level             % activity*	Bleeding Episodes
Severe	<1%	Spontaneous bleeding episodes, predominantly into   joints and muscles   Severe bleeding with trauma, injury or surgery
Moderate	1% to 5%	Occasional spontaneous bleeding episodes   Severe bleeding with trauma, injury or surgery
Mild	6% to 40%	Severe bleeding with serious injury, trauma or surgery

 

 

 

Appendix B: Clinical Reasons For Not Utilizing Desmopressin in Patients with Hemophilia A

1. Age < 2 years
2. Pregnancy
3. Fluid/electrolyte imbalance
4. High risk for cardiovascular or cerebrovascular disease (especially the elderly)
5. Predisposition to thrombus formation
6. Trauma requiring surgery
7. Life-threatening bleed
8. Contraindication or intolerance to desmopressin
9. Stimate Nasal Spray is unavailable due to backorder/shortage issues (where applicable)

 

Place of Service:

Outpatient

The above policy is based on the following references:

1. Hemlibra [package insert]. South San Francisco, CA: Genentech, Inc.; June 2022.
2. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158. doi:1111/hae.14046.
3. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Revised March 2022. MASAC Document #272. https://www.hemophilia.org/sites/default/files/document/files/272_Treatment.pdf. Accessed December 2, 2022.
4. National Hemophilia Foundation. Hemophilia A (Factor VIII Deficiency). Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=180&contentid=45&rptname=bleeding. Accessed December 2, 2022.
5. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed December 2, 2022.
6. Leissinger C, Carcao M, Gill JC, et al. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders. Haemophilia. 2014;20:158-167.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

April 15, 2023